Cargando…

MicroRNAs Distinguish Cytogenetic Subgroups in Pediatric AML and Contribute to Complex Regulatory Networks in AML-Relevant Pathways

BACKGROUND: The role of microRNAs (miRNAs), important post-transcriptional regulators, in the pathogenesis of acute myeloid leukemia (AML) is just emerging and has been mainly studied in adults. First studies in children investigate single selected miRNAs, however, a comprehensive overview of miRNA...

Descripción completa

Detalles Bibliográficos
Autores principales:	Daschkey, Svenja, Röttgers, Silja, Giri, Anamika, Bradtke, Jutta, Teigler-Schlegel, Andrea, Meister, Gunter, Borkhardt, Arndt, Landgraf, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3572007/ https://www.ncbi.nlm.nih.gov/pubmed/23418555 http://dx.doi.org/10.1371/journal.pone.0056334

Ejemplares similares

Optical Genome Mapping for Cytogenetic Diagnostics in AML
por: Nilius-Eliliwi, Verena, et al.
Publicado: (2023)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
por: Islam, Mirazul, et al.
Publicado: (2017)

DNA Methylation Clusters and Their Relation to Cytogenetic Features in Pediatric AML
por: Lamba, Jatinder K., et al.
Publicado: (2020)

AML, NOS and AML-MRC as defined by multilineage dysplasia share a common mutation pattern which is distinct from AML-MRC as defined by MDS-related cytogenetics
por: Fuhrmann, Irene, et al.
Publicado: (2022)

Identification of TEL-AML1 (ETV6-RUNX1) associated DNA and its impact on mRNA and protein output using ChIP, mRNA expression arrays and SILAC
por: Linka, Yvonne, et al.
Publicado: (2014)

Long-term follow-up of cytogenetically normal CEBPA-mutated AML
por: Pastore, Friederike, et al.
Publicado: (2014)

Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004
por: Rasche, M, et al.
Publicado: (2017)

The NPM1 Mutation Type Has No Impact on Survival in Cytogenetically Normal AML
por: Pastore, Friederike, et al.
Publicado: (2014)

IDH Mutations in AML Patients; A higher Association with Intermediate Risk Cytogenetics
por: ElNahass, Yasser H, et al.
Publicado: (2020)

Identification of Survival-Related Genes in Acute Myeloid Leukemia (AML) Based on Cytogenetically Normal AML Samples Using Weighted Gene Coexpression Network Analysis
por: Chen, Tingting, et al.
Publicado: (2022)

Parallel evaluation of cell-based phage display panning strategies: Optimized selection and depletion steps result in AML blast-binding consensus antibodies
por: Weber, Theresa, et al.
Publicado: (2021)

Mutation Patterns of 16 Genes in Primary and Secondary Acute Myeloid Leukemia (AML) with Normal Cytogenetics
por: Fernandez-Mercado, Marta, et al.
Publicado: (2012)

DNA Methylation Signatures Predict Cytogenetic Subtype and Outcome in Pediatric Acute Myeloid Leukemia (AML)
por: Krali, Olga, et al.
Publicado: (2021)

AML1/ETO Oncoprotein Is Directed to AML1 Binding Regions and Co-Localizes with AML1 and HEB on Its Targets
por: Gardini, Alessandro, et al.
Publicado: (2008)

Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
por: Estey, Elihu, et al.
Publicado: (2022)

Clinical, Cytogenetic, and Molecular Findings in Two Cases of Variant t(8;21) Acute Myeloid Leukemia (AML)
por: Wilde, Lindsay, et al.
Publicado: (2019)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT 3‐ITD AML
por: Buelow, Daelynn R., et al.
Publicado: (2019)

Cytogenetic profile of adult AML patients in Turkey: a single center study with comprehensive comparison with literature
por: Cirakoglu, Ayse, et al.
Publicado: (2022)

The role of the proteasome in AML
por: Csizmar, C M, et al.
Publicado: (2016)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

CALCRL Gene is a Suitable Prognostic Factor in AML/ETO(+) AML Patients
por: Wang, Rongrong, et al.
Publicado: (2022)

Quantification of minimal residual disease (MRD) in acute lymphoblastic leukemia (ALL) using amplicon-fusion-site polymerase chain reaction (AFS-PCR)
por: Weber, Axel, et al.
Publicado: (2012)

Acute Myeloid Leukemia (AML) In Elderly: Cytogenetic Characteristics of Patients Treated At Hematology and Pediatric Oncology Center in Casablanca
por: Bendari, Mounia, et al.
Publicado: (2018)

Identification of STAB1 in Multiple Datasets as a Prognostic Factor for Cytogenetically Normal AML: Mechanism and Drug Indications
por: Lin, Sheng-Yan, et al.
Publicado: (2019)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Targeting glutamine uptake in AML
por: Jacque, Nathalie, et al.
Publicado: (2014)

AML treatment in older adults
por: Sehgal, Alison, et al.
Publicado: (2015)

Impact of CNA on AML prognosis
por: Gonzales, Fanny, et al.
Publicado: (2017)

Treatments for children and adolescents with AML
por: Kim, Hyery
Publicado: (2020)

Emerging agents and regimens for AML
por: Liu, Hongtao
Publicado: (2021)

Von AML bis Zytokinfreisetzung
por: Klein, Friederike
Publicado: (2022)

Inherited predisposition to MDS/AML
por: Rio Machin, Ana, et al.
Publicado: (2018)

CEBPA-dependent HK3 and KLF5 expression in primary AML and during AML differentiation
por: Federzoni, Elena A., et al.
Publicado: (2014)

De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2017)

Oncogenic Roles Of A Histone Methyltransferase SETDB2 In AML1-ETO Positive AML
por: Mu, Guangfu, et al.
Publicado: (2020)

IRF8 Is an AML-Specific Susceptibility Factor That Regulates Signaling Pathways and Proliferation of AML Cells
por: Liss, Franziska, et al.
Publicado: (2021)

Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics
por: haes, Inke De, et al.
Publicado: (2020)

The outcomes of secondary AML post allogeneic hematopoietic cell transplantation significantly depend on the presence of poor‐risk cytogenetic abnormalities
por: Hassanein, Mona, et al.
Publicado: (2021)

Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
por: Jacoby, Meagan A., et al.
Publicado: (2021)

CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
por: Tettamanti, Sarah, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_gjrdreld7s4443lhmlcc3pb72e